IGC Pharma completes dosing in Phase 2 trial of IGC-AD1 for Alzheimer's agitation
IGC•IGC Pharma completed six weeks of dosing for all 170 participants in its Phase 2 CALMA trial, exceeding its original enrollment target of 146. Topline results are expected in December 2026 or January 2027.




